Understanding ANI Pharmaceuticals' Earnings Report
ANI Pharmaceuticals (NASDAQ: ANIP) is gearing up for its latest quarterly earnings announcement. Investors are keenly interested in what the report will reveal and how it may impact the company’s future growth trajectory.
Analysts' Earnings Predictions
Market analysts are estimating that ANI Pharmaceuticals will report an earnings per share (EPS) of $1.61. Investors are eager for news that the company may exceed these estimates, which could have positive implications for its stock price and guidance for upcoming quarters.
Recapping Past Earnings Performance
Looking back at the last quarter, ANI Pharmaceuticals managed to beat EPS estimates by $0.54. Interestingly, despite this positive news, shares experienced a slight drop of 0.0% the following day. A historical glance at the company’s earnings shows fluctuations, often leading to volatile responses in the stock market.
Past Earnings Data Summary
In recent quarters, ANI Pharmaceuticals has shown promise with the following EPS measures:
- Q2 2025: EPS Estimate - 1.26, Actual - 1.80, Price Change - 18%
- Q1 2025: EPS Estimate - -0.06, Actual - 1.70, Price Change - -7%
- Q4 2024: EPS Estimate - 0.29, Actual - 1.63, Price Change - 13%
- Q3 2024: EPS Estimate - 1.09, Actual - 1.34, Price Change - 5%
An Insight into Stock Performance
As of early November, ANI Pharmaceuticals shares were trading at approximately $92.62. Over the past 52 weeks, the stock has surged by nearly 50.98%. Given these positive trends, long-term investors may be optimistic leading up to the earnings report.
Analyst Ratings: What They Indicate
Understanding the opinions of market analysts is vital. Currently, ANI Pharmaceuticals holds a consensus rating of Buy, based on six analyst reviews. The average price target for the stock is set at $101.67, suggesting a potential upside of about 9.77%. This reflects a strong belief in the company's prospects moving forward.
Peer Performance Insights
It's beneficial to consider how ANI Pharmaceuticals stacks up against its industry peers. For instance, Perrigo has a Neutral outlook with a target of $21.50, projecting a possible downside of 76.79%. In contrast, Liquidia has a Buy rating with an average target of $42.12, which suggests a notable downside of 54.52%.
Summary of Peer Comparisons
The comparative metrics of ANI Pharmaceuticals, Perrigo, and Liquidia provide a clearer picture of market expectations:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| ANI Pharmaceuticals | Buy | 53.12% | $136.76M | 1.90% |
| Perrigo | Neutral | -0.86% | $362.90M | -0.19% |
| Liquidia | Buy | 1121.72% | $51.17M | -18.97% |
Exploring Company Operations
ANI Pharmaceuticals Inc specializes in the development, manufacturing, and marketing of generic prescription medications. The company’s offerings include a range of products from narcotics to complex formulations. It operates largely in the United States and Canada, with the bulk of its revenue generated in the U.S.
Financial Health Indicators
Market Capitalization: The current market cap of ANI Pharmaceuticals indicates a smaller scale compared to its peers. This may reflect on its perceived growth potential.
Revenue Growth Rate: The company reported a noteworthy revenue growth rate of 53.12% as of the latest quarter, showcasing a significant gain compared to its previous quarters.
Net Margin: ANI’s net margin reaches around 3.85%, indicating effective cost control and healthy finances.
Return on Equity (ROE): With a commendable ROE of 1.90%, ANI demonstrates efficient use of shareholder equity.
Return on Assets (ROA): ANI Pharmaceuticals showcases a strong ROA of about 0.62%, reflecting solid asset management.
Debt Management Strategy: The company maintains a favorable debt-to-equity ratio of 1.42, indicating responsible financial structuring.
Frequently Asked Questions
What is ANI Pharmaceuticals' upcoming quarterly earnings report date?
ANI Pharmaceuticals will report its next quarterly earnings on November 7, 2025.
What are analysts' EPS expectations for ANI Pharmaceuticals?
Analysts anticipate an EPS of $1.61 for the upcoming report.
How have ANI Pharmaceuticals’ shares performed recently?
Shares of ANI Pharmaceuticals have increased by about 50.98% over the past year.
What is the general consensus rating for ANI Pharmaceuticals?
The consensus rating for ANI Pharmaceuticals is currently a Buy based on analyst evaluations.
How does ANI Pharmaceuticals compare to its industry peers?
ANI Pharmaceuticals shows strong revenue growth compared to peers but has mixed results on other metrics like gross profit and return on equity.
